Erdafitinib US Brand Name(s) Balversa
Use in Cancer Treatment
Erdafitinib is to treat the following conditions:
Urothelial carcinoma (a form of bladder cancer) with specific mutations in the FGFR3 gene or a fusion gene involving the FGFR3 gene or the FGFR2 gene that is locally progressing or has metastasizing(spread to other regions of the body). It is for people whose illness has become worse during or after receiving at least one form of platinum chemotherapy.
The FDA’s Accelerated Approval Program has authorized this usage. A confirmatory study (or trials) must prove that erdafitinib offers a therapeutic benefit in these individuals as a condition of approval.
Erdafitinib is also under research for use in the treatment of other cancers.
A pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic action that may be taken orally. Erdafitinib binds to and inhibits FGFR after oral treatment,. Potentially inhibiting FGFR-related signal transduction pathways and, as a result, tumor cell growth and death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase that increases in numerous tumor cell types and is necessary for tumor cell proliferation, differentiation, and survival.
Erdafitinib is a medication used in the treatment of certain types of advanced or metastatic cancer. It is specifically approved for the treatment of locally advanced or metastatic bladder cancer that has a specific genetic alteration called FGFR3 or FGFR2 fusion or other rearrangements. Erdafitinib belongs to a class of drugs called fibroblast growth factor receptor (FGFR) inhibitors.
FGFRs are proteins that play a role in cell growth and division. In some cancers, there can be alterations or mutations in the FGFR genes, leading to abnormal activation of these proteins, which can promote cancer cell growth. Erdafitinib works by inhibiting the activity of FGFRs, thereby helping to slow down or stop the growth of cancer cells.